KLK3 and posterior cortical atrophy: While early-stage PCa can be effectively managed through a radical prostatectomy (RP) and radiotherapy, 20%-50% of PCa patients will experience biochemical recurrence (BCR) within 10 years after initial definitive therapy, characterized by rising serum PSA levels 3.